Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Singhal Priya reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Priya Singhal, Head of Development, received a grant of 10,560 restricted stock units. These RSUs were awarded at no cash cost per unit as part of equity compensation. According to the disclosure, the units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
BIOGEN INC. executive Nicole Murphy reported a grant of 10,560 restricted stock units and a small open-market share purchase. The restricted stock units were awarded on February 13, 2026 and vest in three equal yearly installments starting on the first anniversary of that grant date. On February 12, 2026 she bought 3 shares of Biogen common stock in an open-market transaction at a price of $195.035 per share. Following these transactions, her direct holdings total 19,611.0408 shares of common stock and 10,560 restricted stock units.
Biogen Inc. reported that Chief Financial Officer Robin Kramer acquired 8,450 restricted stock units as a grant on February 13, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting equity-based compensation rather than an open-market purchase.
According to the footnote, these restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. After this grant, Kramer directly holds 8,450 RSUs, which may convert into Biogen shares as they vest.
Keeney Adam reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. executive Adam Keeney, Head of Corporate Development, reported an award of 8,025 restricted stock units. These RSUs were granted at no purchase price and represent the right to receive Biogen common shares upon vesting. The units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
Izzar Rachid reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Rachid Izzar, Head of Global Product Strategy, received a grant of 7,390 restricted stock units. These RSUs were awarded at no cash cost per unit and represent a form of stock-based compensation that aligns the executive’s interests with shareholders.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. The entire 7,390-unit award is reported as directly owned following the transaction.
Grogan Jane reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Head of Research Jane Grogan received a grant of 8,450 restricted stock units (RSUs) on February 13, 2026. These RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, providing her with long-term, equity-based compensation rather than an open-market share purchase or sale.
Gregory Ginger reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Gregory Ginger, EVP of Human Resources, received an equity grant of 8,025 restricted stock units on February 13, 2026. These RSUs were awarded at no cash cost to him as part of his compensation and represent a right to receive Biogen shares in the future.
The 8,025 restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. All units are reported as directly owned following the grant, meaning his reported derivative holdings increased by the full award amount.
Godbout Sean reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. Chief Accounting Officer Sean Godbout reported receiving a grant of 1,800 restricted stock units. These RSUs were awarded at a stated price of $0.00 per unit and increase his directly owned derivative holdings to 1,800 units. According to the footnote, the award vests in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026, meaning one-third of the units will vest each year over a three-year period.
ALEXANDER SUSAN H reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that EVP and Chief Legal Officer Susan H. Alexander received a grant of 8,450 restricted stock units on February 13, 2026. These units represent a form of equity compensation rather than a cash transaction. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date, meaning the award is earned over time as continued service is provided.
Biogen Inc. announced a planned change in its Board leadership. Caroline Dorsa, current Chair of the Board of Directors, informed the company that she will not stand for re-election at the 2026 Annual Meeting of Stockholders. The company states that her decision is not related to any disagreement with the Board or Biogen regarding operations, policies, or practices.
On the same date, Biogen’s Board elected Dr. Maria C. Friere to serve as Chair of the Board, effective after the 2026 Annual Meeting. This provides for an orderly transition in the role of Board Chair following the shareholder meeting.